Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 741.00
+19.00 (2.63%)
Jul 16, 2026, 2:00 PM CST
Lin BioScience Market Cap
Lin BioScience has a market cap or net worth of 59.8 billion as of July 15, 2026. Its market cap has increased by 443.53% in one year.
Market Cap
59.80B
Enterprise Value
57.93B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
741.00
Market Cap Chart
Since October 8, 2018, Lin BioScience's market cap has increased from 2.92B to 59.80B, an increase of 1,950.73%. That is a compound annual growth rate of 47.50%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 15, 2026 | 59.80B | 82.09% |
| Dec 31, 2025 | 32.84B | 203.76% |
| Dec 31, 2024 | 10.81B | 20.85% |
| Dec 29, 2023 | 8.95B | -28.90% |
| Dec 30, 2022 | 12.58B | -1.94% |
| Dec 30, 2021 | 12.83B | 83.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 8, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 167.31B |
| Pell Bio-Med Technology | 58.31B |
| Oneness Biotech | 24.45B |
| CHO Pharma | 23.76B |
| Sunmax Biotechnology | 20.75B |
| TaiMed Biologics | 17.57B |
| Ever Supreme Bio Technology | 17.10B |
| Lumosa Therapeutics | 16.46B |